SCHEMBL25529496

SCHEMBL25529496

O=[N+]([O-])c1cccc(C2=CCOCC2)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S100A4 P26447 2/20 0.37
▸ MAPT P10636 3/20 0.37
▸ RECQL P46063 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ MCL1 Q07820 1/20 0.37
▸ RXFP1 Q9HBX9 1/20 0.37
▸ MAPK14 Q16539 5/20 0.37
▸ TDP1 Q9NUW8 3/20 0.35
▸ CSNK1D P48730 2/20 0.35
▸ CSNK1E P49674 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ PTPRC P08575 1/20 0.35
▸ GPR35 Q9HC97 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ PDCD1 Q15116 1/20 0.34
▸ CD274 Q9NZQ7 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29516860 1.00 S100A4 (0.37) S100A4MAPTRECQLKMT2AMCL1
SCHEMBL27168516 0.81 MAPK14 (0.34) S100A4MAPTRECQLKMT2AMCL1
SCHEMBL26162646 0.80 MAPK14 (0.34) S100A4MAPTRECQLKMT2AMCL1
SCHEMBL27168535 0.80 MAPK14 (0.34) S100A4MAPTRECQLKMT2AMCL1
SCHEMBL27168546 0.78 MAPK14 (0.34) S100A4MAPTRECQLKMT2AMCL1
SCHEMBL29162256 0.78 MAPK14 (0.33) S100A4MAPTRECQLKMT2AMCL1
SCHEMBL26162618 0.77 MAPT (0.39) MAPTRECQLKMT2AMCL1RXFP1
SCHEMBL26162637 0.77 MAPK14 (0.36) S100A4MAPTRECQLKMT2AMCL1
SCHEMBL25197753 0.77 IDH2 (0.36) RECQLMAPK14TDP1ALDH1A1CYP1A2
SCHEMBL29517002 0.77 IDH2 (0.36) RECQLMAPK14TDP1ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637435-B2 Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof FUJIFILM CORPORATION (JP) 2026-05-26 — — US disclosed
US-12421217-B2 Pyrazine derivative or salt thereof, and use of same FUJIFILM CORPORATION (JP) 2025-09-23 — — US disclosed
EP-4190402-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORP (JP) 2025-08-27 — — EP disclosed
EP-4052760-B1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM CORP (JP) 2024-03-13 — — EP disclosed
EP-4190402-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM Corporation (JP) 2023-06-07 — — EP disclosed
EP-4190402-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM Corporation (JP) 2023-06-07 — — EP disclosed
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORPORATION (JP) 2023-06-01 — — US disclosed
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORPORATION (JP) 2023-06-01 — — US disclosed
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORPORATION (JP) 2023-06-01 — — US disclosed
CN-116056766-A Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof 富士胶片株式会社 2023-05-02 — — CN disclosed
EP-4052760-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM Corporation (JP) 2022-09-07 — — EP disclosed
US-20220259185-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME FUJIFILM CORPORATION (JP) 2022-08-18 — — US disclosed
WO-2021085582-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME 富士フイルム株式会社 2021-05-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF DHRS9, DHODH, CBR1 S100A4 2417/4885MAPT 4800/4885RECQL 3165/4885
US-12421217-B2 Pyrazine derivative or salt thereof, and use of same DHODH, IDH1, IDH2 S100A4 4163/4885MAPT 4437/4885RECQL 1091/4885
US-12637435-B2 Nitrogen-containing heterocyclic compound or salt thereof, use thereof, and intermediate thereof CBR1, DHODH, CBR3 S100A4 3990/4885MAPT 4812/4885RECQL 2569/4885
US-20220259185-A1 PYRAZINE DERIVATIVE OR SALT THEREOF, AND USE OF SAME DHODH, IDH1, IDH2 S100A4 4163/4885MAPT 4437/4885RECQL 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback